PCDH17 and neoplasm: PCDH17 promoter methylation was detected in 52.3% of patients with bladder cancer and was associated with larger tumour diameter, high grade and advanced stage. Patients with PCDH17 promoter methylation had significantly shorter overall survival than those with unmethylated PCDH17 promoter.